Last, our work is the first to show that Ampk can have a pro-tumorigenic role in Lkb1 mutant cancer in vivo, and suggests that KRAS/LKB1 mutant lung adenocarcinoma patients may benefit from CAMKK inhibitors. The gene discussed is KRAS; the disease is lung adenocarcinoma.